CBFB-MYH11 is a suspected disease in the field of blood tumors, with clinical performance being complex and often involving multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
Treatment and management of acute myelogenous leukemia requires individualized treatment, typically including drug therapy, rehabilitation intervention, regular follow-up, and multi-dimensional management. In recent years, with the development of targeted therapy, immune regulation therapy, and precision medicine, significant improvements have been made in many previously difficult-to-treat blood tumor diseases. Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adjusting the regimen according to changes in the condition and timing.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of acute myelogenous leukemia. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology, to provide the following services to patients: 1. Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2.
Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: providing one-stop services: providing medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.
Support for remote pre-diagnosis, visiting interviews, full translation and escort.